- Leading institutional investors commit $95 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Fidelity Management & Research Company LLC, ...

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its ...

Pardes Biosciences Inc, an early-stage biopharmaceutical company, has agreed to go public via a merger with FS Development Corp II, a blank check firm backed by Foresite Capital. When the deal closes, ...

FS Development II, the second blank check company formed by Foresite Capital targeting a healthcare business, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Gilead Sciences, RA Capital ...

PHILADELPHIA and NEW YORK, Dec. 18, 2019 /PRNewswire/ -- FS/KKR Advisor, LLC (FS/KKR), a partnership between FS Investments and KKR Credit Advisors (US) LLC, today announced the closing of the mergers ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. South Philadelphia-based FS Investments described the ...

Kevin Silva has been named global head of institutional business development at FS Investments, the $76 billion global alternative asset manager. Silva reports to Enrico Gaglioti, co-president, and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...